1999
DOI: 10.1210/jcem.84.4.5612
|View full text |Cite
|
Sign up to set email alerts
|

Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
40
0

Year Published

2001
2001
2018
2018

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 133 publications
(47 citation statements)
references
References 107 publications
1
40
0
Order By: Relevance
“…It seems to be an ongoing process hardly influenced by concomitant glucose lowering treatment (38). Loss of first-phase insulin response to glucose is an early ␤-cell defect, followed by a weakened basal and second-phase insulin output as the disease progresses (39,40). This, combined with an abnormal circadian glucagon secretory pattern (5,33) and diminished ability of hyperglycemia to suppress glucagon secretion, demonstrates the necessity for opposing both the ␣-and ␤-cell malfunction in the treatment of type 2 diabetes.…”
Section: Discussionmentioning
confidence: 99%
“…It seems to be an ongoing process hardly influenced by concomitant glucose lowering treatment (38). Loss of first-phase insulin response to glucose is an early ␤-cell defect, followed by a weakened basal and second-phase insulin output as the disease progresses (39,40). This, combined with an abnormal circadian glucagon secretory pattern (5,33) and diminished ability of hyperglycemia to suppress glucagon secretion, demonstrates the necessity for opposing both the ␣-and ␤-cell malfunction in the treatment of type 2 diabetes.…”
Section: Discussionmentioning
confidence: 99%
“…Insulin resistance and hyperinsulinemia eventually lead to impaired glucose tolerance [36]. Except for maturity onset diabetes of the young (MODY), the mode of inheritance for type 2 diabetes mellitus is unclear.…”
Section: Type 2 Diabetes Mellitusmentioning
confidence: 99%
“…TRO is an agonist of the peroxisome proliferator-activated receptor ␥ (PPAR␥) (Lehmann et al, 1995;Mahler and Adler, 1999) that sensitizes target cells to insulin, thereby improving the metabolic conditions associated with adult-onset diabetes. Although the precise mechanism of action of TRO is still not fully understood, the insulin-sensitizing effects of TRO are believed to be mediated through the activation of PPAR␥.…”
mentioning
confidence: 99%